Tumor Heterogeneity and Drug Resistance Mutations Using ctDNA in Metastatic EGFR Mutation-Positive Lung Adenocarcinoma: A Case Report
Jinghua Sun,Ge Sun,KeMou Lu,Lingling Xu,XiaoNa Qu,Ye Cheng,Evenki Pan,Peng Yang,Tingting Wu,Yang Zhang,HongMei He
DOI: https://doi.org/10.2147/ott.s376647
IF: 4
2022-08-30
OncoTargets and Therapy
Abstract:Jinghua Sun, 1, &ast Ge Sun, 1, &ast KeMou Lu, 1 Lingling Xu, 1 XiaoNa Qu, 1 Ye Cheng, 1 Evenki Pan, 2 Peng Yang, 2 Tingting Wu, 2 Yang Zhang, 1 HongMei He 1 1 The Second Affiliated Hospital of Dalian Medical University, Dalian, People's Republic of China; 2 Nanjing Geneseeq Technology Inc., Nanjing, People's Republic of China &astThese authors contributed equally to this work Correspondence: Yang Zhang; HongMei He, The Second Affiliated Hospital of Dalian Medical University, Dalian, No. 467, Zhongshan Road, Shahekou District, Dalian, People's Republic of China, Email ; For advanced non-small cell lung cancer (NSCLC) patients with epidermal growth factor receptor ( EGFR ) mutations, EGFR tyrosine kinase inhibitors (TKIs) have been approved as the standard therapy and shown clinical benefits. However, the emergence of drug resistance is inevitable. Tumor heterogeneity was often observed by imaging method to evaluate the progression of primary and metastatic lesions. Tissue biopsy was also unlikely to accurately capture the complete genomic landscape from a single tissue sample. Recently, genomic characterization of circulating tumor DNA (ctDNA) offer an opportunity to reveal the clonal dynamics throughout the course of a patient's illness and provide comprehensive genomic landscape of tumors to assess tumor heterogeneity. Here, we reported a lung adenocarcinoma (LADC) with EGFR mutations who was treated with sequential EGFR TKIs. The CT image of the patient's different lesions suggested that dynamic change of tumor heterogeneity had occurred. Targeted next-generation sequencing (NGS) analysis of ctDNA revealed dynamic changes of mutational profiles between the primary and metastatic tumors to discover tumor evolution to guide treatment decision-making. Keywords: tumor heterogeneity, circulating tumor DNA, ctDNA, resistance mutation, next-generation sequencing, NGS In Asian non-small cell lung cancer (NSCLC) patients, somatic activating mutations in the epidermal growth factor receptor ( EGFR ) such as point mutation L858R within exon 21 and short in-frame deletions within exon 19 are the most common oncogenic driver mutation. 1 With the development of targeted therapy and next-generation sequencing (NGS) technology, the therapeutic strategies for lung cancer have evolved into a new era of genomics-guided precision medicine. These EGFR -targeted tyrosine kinase inhibitors (TKIs) have shown improved tumor response and progression-free survival (PFS) outcome in EGFR -mutated NSCLC. 2 Although EGFR T790M mutation have been confirmed as first- and second-generation EGFR -TKIs resistance mutations, a third-generation EGFR -TKI of osimertinib has shown efficacy in counteracting the growth of EGFR T790M mutant tumors. 3 Although osimertinib has demonstrated high clinical efficacy, developing resistance is also inevitable. The biggest hurdle for the successful treatment of cancer is the tumor heterogeneity, which can take different forms of intratumor, intermetastatic or intrametastatic heterogeneity within an individual patient. 4 Computed tomography (CT) remains the initial imaging method for clinical staging of lung cancer, evaluating the change of primary and metastatic lesions. Recently, gene sequencing of circulating tumor DNA (ctDNA) from a liquid biopsy or blood sample can provide comprehensive genetic information of all cancerous lesions (primary and metastases), which overcomes spatial and temporal heterogeneity of a single-tumor biopsy sample, as well as facilitates dynamic tracking of genomic evolution for formatting a treatment strategy. 5 We herein report a case of lung adenocarcinoma (LADC) with EGFR mutations, whose different tumor lesions exhibited different response to the EGFR -TKIs. The NGS analysis of ctDNA revealed dynamic changes of mutational profiles between the primary and metastatic tumors. A 44-year-old female was diagnosed with stage IV LADC (cT2bN2M1c) in the right lung center with lymph nodes metastases in February 2017. Positron emission tomography-computed tomography (PET-CT) scan indicated a 14×9 mm density mass in the upper lobe of right lung and a 23×7 mm density mass in the right hilum, respectively (Figure 1). Immunohistochemistry (IHC) staining of tumor biopsy showed positive for LADC markers thyroid transcription factor-1 (TTF-1) and Napsin-A, but negative for lung squamous cell carcinoma (LSCC) markers P40 and P63. NGS demonstrated EGFR L858R with a mutation allelic frequency (MAF) of 0.5%, in plasma and 19.7% in tumor tissue of the upp -Abstract Truncated-
oncology,biotechnology & applied microbiology